Cancer Family
Mesothelial Neoplasm
CI-CAN-00000028Explore in graph →
Non-malignant108 active trials4 approved drugs13 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000028Explore in graph →
Clinical trials
521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05041062 | A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma | completed | Phase 2 | 2 | University of ChicagoOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT03399552 | Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma | completed | Phase 1 / Phase 2 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT02709512 | Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(ATOMIC) | completed | Phase 2 / Phase 3 | 249 | Polaris GroupINDUSTRY | 5 | Oct 4, 2023 | clinicaltrials |
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | completed | Phase 2 | 37 | University of FloridaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT01486368 | A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma | completed | Phase 2 | 17 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02899195 | Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma(PrE0505) | completed | Phase 2 | 55 | PrECOG, LLC.OTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT00101283 | Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma | completed | Phase 2 | 32 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS) | withdrawn | Phase 2 | 0 | Translational Research in OncologyOTHER | 0 | Jun 7, 2023 | clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT04940637 | UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC(UNITO-001) | unknown | Phase 2 | 70 | University of Turin, ItalyOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT04115111 | Diadem to Investigate the Activity and Safety of Durvalumab(Diadem) | completed | Phase 2 | 57 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT00651456 | Mesothelioma Avastin Plus Pemetrexed-cisplatin Study(MAPS) | completed | Phase 2 / Phase 3 | 448 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02414945 | TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients | completed | Phase 1 / Phase 2 | 9 | University Health Network, TorontoOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT02436733 | Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM | unknown | Phase 2 | 64 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Nov 7, 2022 | clinicaltrials |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT02293005 | Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma | completed | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT02592551 | MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma | completed | Phase 2 | 24 | Baylor College of MedicineOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT00738582 | An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma(Amatuximab) | completed | Phase 2 | 89 | MorphotekINDUSTRY | 5 | Sep 22, 2022 | clinicaltrials |
| NCT04013334 | MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma | unknown | Phase 2 | 12 | Momotaro-Gene Inc.INDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT02385812 | Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma | terminated | Phase 2 | 200 | University of CalgaryOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT02347917 | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 28 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02859415 | Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02568449 | Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT03644550 | Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Dec 2, 2021 | clinicaltrials |
| NCT02139904 | Vinorelbine in Mesothelioma(VIM) | completed | Phase 2 | 154 | Wales Cancer Trials UnitOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT01644994 | Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 47 | University of ZurichOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma | terminated | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT01085630 | Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy | completed | Phase 2 | 72 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 18, 2021 | clinicaltrials |
| NCT00700336 | Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) | completed | Phase 1 / Phase 2 | 69 | CanBas Co. Ltd.INDUSTRY | 1 | Jul 20, 2021 | clinicaltrials |
| NCT03213301 | Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. | completed | Phase 2 | 42 | Swiss Cancer InstituteOTHER | 2 | Jul 14, 2021 | clinicaltrials |
| NCT03786419 | A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma | withdrawn | Phase 2 | 0 | Health Pharma Professional ResearchOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT00003508 | Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma | terminated | Phase 2 | 8 | Burzynski Research InstituteOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT02860286 | Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma | completed | Phase 2 | 74 | Epizyme, Inc.INDUSTRY | 3 | Apr 9, 2021 | clinicaltrials |
| NCT03531840 | Olaparib in People With Malignant Mesothelioma | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Apr 9, 2021 | clinicaltrials |
| NCT02716272 | Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients(MAPS2) | completed | Phase 2 | 125 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT04713761 | Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma | unknown | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Jan 26, 2021 | clinicaltrials |
| NCT02049060 | Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin | completed | Phase 1 / Phase 2 | 31 | Armando Santoro, MDOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT02303899 | Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma | completed | Phase 2 | 22 | Istituto Clinico HumanitasOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT03048474 | Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma(INITIATE) | completed | Phase 2 | 36 | The Netherlands Cancer InstituteOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT02610140 | Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) | completed | Phase 2 | 248 | BayerINDUSTRY | 14 | Nov 4, 2020 | clinicaltrials |
| NCT00295503 | Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma | completed | Phase 2 | 53 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT03177668 | Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 40 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 25, 2020 | clinicaltrials |
| NCT00859495 | Trimodal Lung-Sparing Treatment of Pleural Mesothelioma | terminated | Phase 2 | 9 | Columbia UniversityOTHER | 1 | Aug 25, 2020 | clinicaltrials |
| NCT00024076 | Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer | completed | Phase 2 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT02151448 | αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies | completed | Phase 1 / Phase 2 | 64 | David BartlettOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT04462809 | Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma(TALAMESO) | unknown | Phase 2 | 40 | Hospices Civils de LyonOTHER | 0 | Jul 9, 2020 | clinicaltrials |
| NCT04290325 | HMPL-453 in Advanced Malignant Mesothelioma | unknown | Phase 2 | 27 | Hutchison Medipharma LimitedINDUSTRY | 1 | Jun 16, 2020 | clinicaltrials |
| NCT01112293 | Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma | completed | Phase 2 | 14 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 10, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jan 3, 2024source: clinicaltrials